However, the two market leaders could have significant competition on the way. Roche Holding (RHHBY 0.23%) underscored this last week with a major clinical study update. Shares of Lilly and Novo Nordisk fell on the news, while Roche's shares jumped nearly 6%. Could Roche be the obesity drug stock to really watch? Patients receiving CT-996 experienced weight loss of 7.3% after four weeks of treatment. Roche stated this result was "clinically meaningful" compared to the 1.2% weight loss for patients receiving ...

This company hasn't made its debut on the weight-loss market yet, but it may. First things first. Appreciate that Roche's weight-loss pill program is currently in phase 1 clinical trials. The first two parts of the three-part trial are done, and the third hasn't started yet. It will need plenty more research and development (R&D) work before it's ready to submit to regulators for approval, assuming it ever is. Any early results may or may not be substantiated by subsequent clinical investigations. Another m ...

Notably, RHHBY stock has underperformed the broader market in each of the last 3 years. Returns for the stock were 18% in 2021, -24% in 2022, and -7% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that RHHBY underperformed the S&P in 2021, 2022, and 2023. Roche's revenue has declined 7.2% from $72.4 billion in 2021 to $67.2 billion in 2023. This can primarily be attributed to lower demand for its Covid-19 testing. Excluding the Covid-19 prod ...

Shares of several obesity-focused stocks dropped on Wednesday after Swiss pharma giant Roche (RHHBY) announced positive top-line results from an early-stage study on its experimental obesity drug CT-996. Both these incretin-based candidates were added to Roche's pipeline from the acquisition of privately owned Carmot Therapeutics for $2.7 billion in January. The acquisition also added CT-868, a once-daily, subcutaneously injected drug, which is being developed in a mid-stage study as a first-in-class treatm ...

Two-year Phase III data presented at ASRS 2024 show Susvimo's potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) Safety data were consistent with the known safety profile for Susvimo in people with DME and DR Additionally, the US FDA has accepted the filing application for Susvimo in DME and DR based on one-year Pagoda and Pavilion study data Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye throug ...

Roche has a robust Phase III clinical development programme for Vabysmo. The programme includes AVONELLE-X (NCT04777201), an extension study of TENAYA (NCT03823287) and LUCERNE (NCT03823300), evaluating the long-term safety and tolerability of Vabysmo in neovascular or 'wet' agerelated macular degeneration (nAMD).17 Roche has also initiated several Phase IV studies, including the ELEVATUM (NCT05224102) study of Vabysmo in underrepresented patient populations with diabetic macular edema, the SALWEEN study of ...

Roche announced strong early stage data from its weight-loss drug CT-996. The once-daily pill delivered placebo-adjusted mean weight loss of 6.1% in obesity patients without diabetes. CT-996 represent possible competition to popular weight-loss drugs Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Roche Added Drug To Pipeline With Carmot Therapeutics Acquisition tips@investopedia.com A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, ...

Topline Roche said it had promising results from an ongoing trial for its obesity pill and would progress to ... [+] midstage trials. Roche said patients taking its experimental once-daily oral drug, CT-996, for four weeks lost an average of 6.1% of their starting bodyweight compared to patients who received a placebo. The CT-996 drug belongs to the same family of GLP-1 hormone mimicking drugs as blockbuster injections like Ozempic, Wegovy, Mounjaro and Zepbound and Roche said the study indicates it is safe ...

Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate. The Swiss pharmaceutical giant said Wednesday that a second drug candidate from its purchase of Carmot Therapeutics indicated positive results, further heating up competition in the weight loss drug market. Roche shares jumped in early deals and were trading 5.87% higher as of 11:17 a.m. London time. Shares of Wegovy-maker Novo Nordisk fell 3.77%, while Zepbound pro ...

After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001)1 Pharmacokinetic data supports a once-daily oral dosing regimen for CT-9961 The safety and tolerability profile was consistent with other oral GLP-1 receptor agonists and no unexpected safety signals were observed1 Obesity is one of the most urgent health challenges in the world with extensive comorbidities, such as type 2 diabetes, cardiovascular disease, liver disease, an ...